Abstract:<span class="paragraphSection">BackgroundLarotrectinib is the first therapy approved in the U.S. for locally advanced or metastatic solid tumors with neurotropic tyrosine receptor kinase (NTRK) gene fusions. NTRK gene fusions have been documented with variable frequency across numerous tumor types; limited data exist regarding the relationship of NTRK gene fusions with other targetable biomarkers. This study evaluated the co-occurrence of NTRK gene fusions with other therapy molecular markers in cancer patients.MethodsThis retrospective study included cancer patients from a de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB) who had next-generation sequencing (NGS) between Jan 2011 and July 2018. The co-occurrence frequencies of NTRK gene fusions with the following markers was determined using NGS assays including FoundationOne and FoundationOne Heme: tumor mutation burden (TMB), microsatellite instability (MSI), ALK, BRAF, ERBB2, EGFR, ROS1, and KRAS.ResultsAn evaluable sample of 15,971 of 33,398 patients in the CGDB had one of 18 histologies where at least one NTRK fusion patient was identified. NTRK gene fusions were identified in 29 patients: 55% (16/29) were female; 69% (20/29) were Caucasians. The median age was 60 years (Q1-Q3: 49.0-65.0). Fifteen different fusion partners were identified; the most frequent were ETV6-NTRK3 (n = 8), TPM3-NTRK1 (n = 6), and TPR-NTRK1 (n = 3). Co-occurring genomic alterations are shown in the table. Table: 102PCo-occurring biomarkers**Patients with NTRK gene fusions (N = 29), % (n)TMB High (>20 mut/mB) TMB Medium (<20, >5 mut/mB)20.7 (6/29) 10.3 (3/29)MSI (high)17.6 (3/17)****ALK rearrangement0.0 (0/29)BRAF alteration3.5 (1/29)ERBB2 amplification0.0 (0/29)EGFR alteration3.5 (1/29)ROS1 alteration0.0 (0/29)KRAS alteration10.3 (3/29)*Variants of "known" or "likely" functional status were included**MSI status missing for 12 patientsConclusionsThe study confirmed the rarity of NTRK gene fusions in cancer patients. Co-occurrence of the biomarkers ALK, BRAF, ERBB2, EGFR, ROS1, or KRAS was uncommon. These results highlight the importance of identifying patients with NTRK gene fusion-driven cancers, through molecular testing, who will benefit from the use of selective TRK kinase inhibitors across different solid tumors.Editorial acknowledgementMichael Sheldon, PhD, of Scion, London, UK, funded by Bayer.Legal entity responsible for the studyBayer.FundingBayer.DisclosureX. Jiao: Full / Part-time employment: Bayer. A. Lokker: Full / Part-time employment: Flatiron Health; Shareholder / Stockholder / Stock options: CVS Health, Roche, Medtronic, Sangamo Therapeutics. J. Snider: Full / Part-time employment: Flatiron Health; Shareholder / Stockholder / Stock options: Roche. E. Castellanos: Full / Part-time employment: Flatiron Health. S. Nanda: Full / Part-time employment: Bayer. V. Fisher: Full / Part-time employment: Foundation Medicine. J. Zong: Full / Part-time employment: Bayer. K. Keating: Full / Part-time employment: Bayer. M. Fellous: Full / Part-time employment: Bayer.</span>

Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland

Characterization of NTRK gene fusion events in solid tumors among Chinese patients.

The landscape of cancer-associated transcript fusions in adult brain tumors: a longitudinal assessment in 140 patients with cerebral gliomas and brain metastases

Large-Scale Study Of Ntrk Fusions In Chinese Solid Tumors And Using Next Generation Sequencing: A Multicenter Study

Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients

Prevalence and clinico-genomic characteristics of patients with TRK fusion cancer in China

Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers

Prevalence of neurotrophic tropomyosin receptor kinase (NTRK) fusion gene positivity in patients with solid tumors in Japan

NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors

China Special Issue on Gastrointestinal Tumors—ntrk Fusion in a Large Real‐world Population and Clinical Utility of Circulating Tumor DNA Genotyping to Guide TRK Inhibitor Treatment

Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.

Genomic Characterization and Outcome Evaluation of Kinome Fusions in a Large Non-Small Cell Lung Cancer Population.

NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities

Imaging characterization of paediatric tumours with the neurotrophic tyrosine receptor kinase fusion transcript

Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib

The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.

NTRK -rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China

NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance

Systematic review of NTRK 1/2/3 fusion prevalence pan-cancer and across solid tumours

NTRK fusions in lung cancer: From biology to therapy

Rare Oncogenic Fusions in Pediatric Central Nervous System Tumors: A Case Series and Literature Review